Experimental human challenge infections can accelerate clinical malaria vaccine development

被引：206

作者：

Sauerwein, Robert W. ^{[1
]}

Roestenberg, Meta ^{[1
]}

Moorthy, Vasee S. ^{[2
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands

[2] WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland

来源：

NATURE REVIEWS IMMUNOLOGY | 2011年 / 11卷 / 01期

关键词：

CIRCUMSPOROZOITE PROTEIN VACCINE; PRIME-BOOST IMMUNIZATION; PHASE I/IIA SAFETY; PLASMODIUM-FALCIPARUM; SPOROZOITE VACCINE; HUMAN VOLUNTEERS; NAIVE ADULTS; VIRUS ANKARA; GROWTH-RATES; DOUBLE-BLIND;

D O I：

10.1038/nri2902

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1 million deaths and an estimated 243 million clinical cases annually. Several candidate malaria vaccines have reached Phase IIb clinical trials, but results have often been disappointing. As an alternative to these Phase IIb field trials, the efficacy of candidate malaria vaccines can first be assessed through the deliberate exposure of participants to the bites of infectious mosquitoes (sporozoite challenge) or to an inoculum of blood-stage parasites (blood-stage challenge). With an increasing number of malaria vaccine candidates being developed, should human malaria challenge models be more widely used to reduce cost and time investments? This article reviews previous experience with both the sporozoite and blood-stage human malaria challenge models and provides future perspectives for these models in malaria vaccine development.

引用

页码：57 / 64

页数：8

共 81 条

[11]

CLYDE DF, 1990, B WORLD HEALTH ORGAN, V68, P9

[12] Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+T cells but does not protect against experimental Plasmodium falciparum infection [J].

Cummings, James F. ;

Spring, Michele D. ;

Schwenk, Robert J. ;

Ockenhouse, Christian F. ;

Kester, Kent E. ;

Polhemus, Mark E. ;

Walsh, Douglas S. ;

Yoon, In-Kyu ;

Prosperi, Christine ;

Juompan, Laure Y. ;

Lanar, David E. ;

Krzych, Urszula ;

Hall, B. Ted ;

Ware, Lisa A. ;

Stewart, V. Ann ;

Williams, Jack ;

Dowler, Megan ;

Nielsen, Robin K. ;

Hillier, Collette J. ;

Giersing, Birgitte K. ;

Dubovsky, Filip ;

Malkin, Elissa ;

Tucker, Kathryn ;

Dubois, Marie-Claude ;

Cohen, Joe D. ;

Ballou, W. Ripley ;

Heppner, D. Gray, Jr. .

VACCINE, 2010, 28 (31) :5135-5144

[13] The expanding vaccine development pipeline, 1995-2008 [J].

Davis, Matthew M. ;

Butchart, Amy T. ;

Coleman, Margaret S. ;

Singer, Dianne C. ;

Wheeler, John R. C. ;

Pok, Angela ;

Freed, Gary L. .

VACCINE, 2010, 28 (05) :1353-1356

[14] Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals [J].

Dietz, Klaus ;

Raddatz, Guednter ;

Molineaux, Louis .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (02) :46-55

[15] A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge [J].

Dunachie, S. J. ;

Walther, M. ;

Epstein, J. E. ;

Keating, S. . ;

Berthoud, T. ;

Andrews, L. ;

Andersen, R. F. ;

Bejon, P. ;

Goonetilleke, N. ;

Poulton, I. ;

Webster, D. P. ;

Butcher, G. ;

Watkins, K. ;

Sinden, R. E. ;

Levine, G. L. ;

Richie, T. L. ;

Schneider, J. ;

Kaslow, D. ;

Gilbert, S. C. ;

Carucci, D. J. ;

Hill, A. V. S. .

INFECTION AND IMMUNITY, 2006, 74 (10) :5933-5942

[16] A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS [J].

Dunachie, SJ ;

Walther, M ;

Vuola, JM ;

Webster, DP ;

Keating, SM ;

Berthoud, T ;

Andrews, L ;

Bejon, P ;

Poulton, I ;

Butcher, G ;

Watkins, K ;

Sinden, RE ;

Leach, A ;

Moris, P ;

Tornieporth, N ;

Schneider, J ;

Dubovsky, F ;

Tierney, E ;

Williams, J ;

Heppner, DG ;

Gilbert, SC ;

Cohen, J ;

Hill, AVS .

VACCINE, 2006, 24 (15) :2850-2859

[17] HUMORAL IMMUNE-RESPONSES IN VOLUNTEERS IMMUNIZED WITH IRRADIATED PLASMODIUM-FALCIPARUM SPOROZOITES [J].

EGAN, JE ;

HOFFMAN, SL ;

HAYNES, JD ;

SADOFF, JC ;

SCHNEIDER, I ;

GRAU, GE ;

HOLLINGDALE, MR ;

BALLOU, WR ;

GORDON, DM .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1993, 49 (02) :166-173

[18] Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes:: An update [J].

Epstein, Judith E. ;

Rao, Suchitra ;

Williams, Frank ;

Freilich, Daniel ;

Luke, Thomas ;

Sedegah, Martha ;

de la Vega, Patricia ;

Sacci, John ;

Richie, Thomas L. ;

Hoffman, Stephen L. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (01) :145-154

[19] Molecular monitoring in malaria vaccine trials [J].

Felger, I ;

Genton, B ;

Smith, T ;

Tanner, M ;

Beck, HP .

TRENDS IN PARASITOLOGY, 2003, 19 (02) :60-63

[20] SAFETY, IMMUNOGENICITY, AND EFFICACY OF A PLASMODIUM-FALCIPARUM VACCINE COMPRISING A CIRCUMSPOROZOITE PROTEIN REPEAT REGION PEPTIDE CONJUGATED TO PSEUDOMONAS-AERUGINOSA TOXIN-A [J].

FRIES, LF ;

GORDON, DM ;

SCHNEIDER, I ;

BEIER, JC ;

LONG, GW ;

GROSS, M ;

QUE, JU ;

CRYZ, SJ ;

SADOFF, JC .

INFECTION AND IMMUNITY, 1992, 60 (05) :1834-1839

← 1 2 3 4 5 6 7 8 9 →